Photo by Kwanchai Lerttanapunyapron/EyeEm/Getty Images
PathAI, a Boston-based artificial intelligence pathology company, has closed a Series C funding round worth $165 million.
The round was co-led by D1 Capital Partners and Kaiser Permanente, with additional participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, and strategic partners Bristol-Myers Squibb Company, Labcorp and Merck Global Health Innovation Fund.
With the new funds, PathAI plans to accelerate product development to expand its suite of applications beyond oncology and nonalcoholic steatohepatitis. It will also seek new partnerships with pharmaceutical and diagnostic organizations.
Artificial raises $21M led by Microsoft s M12 for a lab automation platform aimed at life sciences R&D – TechCrunch
techcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techcrunch.com Daily Mail and Mail on Sunday newspapers.
Giải đấu Liên Quân quốc tế AWC chính thức trở lại: Việt Nam có 3 suất tham dự, giải thưởng 12 tỷ, sẽ thi đấu online - eSport
vietgiaitri.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietgiaitri.com Daily Mail and Mail on Sunday newspapers.